PEPTIDE TECHNOLOGIES, INC. - FORM 8-K - December 17, 2012
UNITED STATESSECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report: December 13, 2012
PEPTIDE TECHNOLOGIES, INC.
(Exact name of registrant as specified in its charter)
--------------------------
Nevada 333-133347 98-0479983
(State or other (Commission File (IRS Employer
jurisdiction of Number) Number)
incorporation)
601 Union Street, Two Union Square, 42nd Floor, Seattle, Washington 98101
(Address of Principal Executive Offices) (Zip Code)
--------------------------------------------------------------------------
(206) 388-5498
--------------
Registrant's telephone number, including area code
Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions:
[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act
(17 CFR 240.14a-12)
[ ] Pre-commencement communications pursuant to Rule
14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the
Exchange Act (17 CFR 240.13e-4(c))
SECTION 1 - REGISTRANT'S BUSINESS AND OPERATIONS
Item 1.01 Entry into a Material Definitive Agreement.
On December 11, 2012, the Company formerly engaged BB&T Capital Markets
("BB&TCM") to act as the Company's exclusive financial advisor and agent in
connection with developing strategic alternatives for the Company regarding debt
financings, licensing of intellectual properties developed by the Company,
equity raises, sale of intellectual properties, or other capital markets
transactions that may develop over the course of a 24 month agreement.
The Company will pay BB&TCM an advisory fee of three percent of the face amount
of the financial transactions advised upon during the course of the engagement,
due and payable at closing.
Additionally, the Company will defend, indemnify and hold BB&TCM, its parent
company, subsidiaries and affiliates and its and their directors, officers,
employees, agents and successors and assigns harmless from and against any
losses, suits, actions, claims, damages, costs and or other liabilities which
any indemnified person may incur as a result of acting on behalf of the Company
in connection with this engagement.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this Report to be signed on its behalf by the
undersigned, hereunto duly authorized.
PEPTIDE TECHNOLOGIES, INC.
By: /s/Scott McKinley
---------------
Scott McKinleyChairman of the Board
Date: December 13, 201
User Contributions:
Comment about this document or add new information about this topic:
This web site and associated pages are not associated with, endorsed by, or sponsored by PEPTIDE TECHNOLOGIES, INC. and has no official or unofficial affiliation with PEPTIDE TECHNOLOGIES, INC.
Based on public records. Inadvertent errors are possible.
Faqs.org does not guarantee the accuracy or timeliness of any information on this site. Use at your own risk.
This website is not associated with the SEC
Some parts © 2013 Advameg, Inc.
